Alosetron: An Effective Treatment for Diarrhea-Predominant Irritable Bowel Syndrome | Zendy

Lucinda A. Harris | Zendy; Lin Chang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alosetron: An Effective Treatment for Diarrhea-Predominant Irritable Bowel Syndrome

Author(s) -

Lucinda A. Harris,

Lin Chang

Publication year - 2006

Publication title -

women s health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.363

H-Index - 39

eISSN - 1745-5065

pISSN - 1745-5057

DOI - 10.2217/17455057.3.1.15

Subject(s) - irritable bowel syndrome , medicine , diarrhea , ondansetron , nausea , granisetron , vomiting , serotonin antagonists , loperamide , gastroenterology , serotonin , 5 ht receptor , receptor , antiemetic

Serotonin (5-HT) is one of the key mediators of gut motility, secretion and sensation. Most 5-HT is localized in the gastrointestinal tract. Particularly important for gut function and regulation are the 5-HT 1P , 5-HT 3 and 5-HT 4 receptors. These receptors have been the focus of research evaluating the pathophysiologic mechanisms of irritable bowel syndrome (IBS) as well as targets for the development of novel agents to treat irritable bowel syndrome. Alosetron is one of three 5-HT 3 antagonists currently available. The other two, ondansetron and granisetron, are primarily used in the treatment of chemotherapy-induced nausea and vomiting. Alosetron, which slows gut transit, has been approved for the treatment of severe diarrhea-predominant IBS (IBS-D) in women. This review will examine the common, yet therapeutically challenging, disorder IBS, as well as the role of alosetron in the treatment of IBS-D.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research